Petros Pharmaceuticals (NASDAQ:PTPI) and MoonLake Immunotherapeutics (NASDAQ:MLTX) Head to Head Comparison

Petros Pharmaceuticals (NASDAQ:PTPI) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Profitability

This table compares Petros Pharmaceuticals and MoonLake Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
MoonLake Immunotherapeutics	N/A	-15.54%	-15.09%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Petros Pharmaceuticals and MoonLake Immunotherapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0	0	0	0	0.00
MoonLake Immunotherapeutics	0	1	6	1	3.00

MoonLake Immunotherapeutics has a consensus target price of $84.29, suggesting a potential upside of 92.39%. Given MoonLake Immunotherapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Petros Pharmaceuticals.

Insider and Institutional Ownership

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Petros Pharmaceuticals has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.

Earnings & Valuation

This table compares Petros Pharmaceuticals and MoonLake Immunotherapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.82 million	0.52	-$8.16 million	($4.76)	-0.06
MoonLake Immunotherapeutics	N/A	N/A	-$36.01 million	($1.29)	-33.96

Petros Pharmaceuticals has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

MoonLake Immunotherapeutics beats Petros Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.